Evidence map›Paper›PMID 29962684›Full record

ArticleJournal of medical physics

Dosimetric Comparison of Irregular Surface Compensator and Field-in-Field for Whole Breast Radiotherapy.

Nao Kuwahata, Hideki Fujita, Hideaki Yamanishi, Eiichiro Okazaki, Haruyuki Fukuda

Abstract read
In one paragraph

Article in Journal of medical physics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Dosimetric evaluation of irregular surface compensator and intensity-modulated radiotherapy in breast radiotherapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2021
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nao KuwahataDepartment of Radiation Oncology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
Hideki FujitaDepartment of Radiation Oncology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
Hideaki YamanishiDepartment of Radiation Oncology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
Eiichiro OkazakiDepartment of Radiation Oncology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
Haruyuki FukudaDepartment of Radiation Oncology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of the present study was to evaluate the dosimetric benefits of the irregular surface compensator (ISC) technique for whole breast radiotherapy compared with the field-in-field (FIF) technique. MATERIALS AND

methodsRadiotherapy was planned using both techniques in 50 breast cancer patients (25 left sided and 25 right sided). The Eclipse treatment planning system (Varian Medical Systems) was used for dose calculations. For the FIF technique, subfields were added to the main fields to reduce hot and cold regions; for the ISC technique, the fluence editor application was used to extend the optimal fluence. Planning target volume dose, dose homogeneity index (DHI), maximum dose, ipsilateral lung, and heart doses for the left breast irradiation and monitor unit (MU) counts required for treatment were compared between the two techniques.

resultsCompared with the FIF technique, the ISC technique significantly decreased DHI values and volumes receiving >105% of the prescription dose, and increased volumes receiving >95% of the dose and MU count (

conclusionsThe ISC technique is preferred over the FIF technique.

Indexed as

Dose distributionfield-in-fieldirregular surface compensatorwhole breast radiotherapy

Identifiers

PMID29962684
PMCPMC6020626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.